SUPN Supernus Pharmaceuticals Inc.

27.11
+0.1  (+0%)
Previous Close 27.01
Open 27.18
Price To Book 2.72
Market Cap 1,421,893,366
Shares 52,449,036
Volume 441,383
Short Ratio
Av. Daily Volume 487,423

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved October 22, 2017.
Oxtellar
Epilepsy
NDA filing due 2H 2019.
SPN-812 (P301)
ADHD
Phase 3 data due 4Q 2019.
SPN-810
Impulsive Aggression in ADHD
Approved Aug 19, 2013.
Trokendi
Epilepsy
Tentative approval August 19 2016, subject to the pediatric exclusivity which expires March 28, 2017. Final approval announced April 6, 2017.
Trokendi
Migraine
FDA approval announced December 14, 2018 to expand label to include monotherapy treatment.
Oxtellar XR
Epilepsy
Phase 3 data trial to be initiated 4Q 2019.
SPN-604
Bipolar depression
Phase 3 data due 1Q 2020.
SPN-810 (P302)
Attention Deficit Hyperactivity Disorder (ADHD)